Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Inclusion Criteria: 1. Voluntary and sign a consent form; 2. Age 3-15 years old, gender unlimited; 3. Histology or imaging diagnosed as diffuse intrinsic pontine glioma, patients haven't received any anti-tumor treatment; 4. According to the RANO criteria, at least one measurable lesion; 5. Before enrollment, the results of laboratory examination are in accordance with: Blood routine test: platelet count ≥ 100 × 10\^9/L; absolute neutrophil count ≥ 1.5 × 10\^9/L or leukocyte count ≥ 3.0 × 10\^9/L; hemoglobin ≥ 90g/L; Blood biochemistry: aspartate aminotransferase#AST# ≤ 3 ×Upper Limit Of Normal#ULN#; alanine aminotransferase#ALT# ≤ 3 × ULN; total bilirubin ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN; 6. Lansky score ≥ 60; 7. Expected survival time ≥ 3 months; 8. Fertile subjects are willing to take contraceptive measures during the study period. Exclusion Criteria: 1. Recurrent DIPG; 2. Have received any other anti-tumor treatment for DIPG, including surgical treatment (except biopsy), chemotherapy, radiotherapy, targeted drugs, immunotherapy, etc; 3. Uncontrollable infection, epilepsy and / or hypertension and / or hyperglycemia; 4. Human immunodeficiency virus #HIV# infection or active hepatitis B infection or hepatitis C infection; 5. Active hemorrhage found by CT or MRI before inclusion and / or inability to carry out CT and MRI examination; 6. Major operation (except biopsy) were performed within four weeks before inclusion; 7. Decompensated heart failure (NYHA grades III and IV), unstable angina, acute myocardial infarction, persistent and clinically significant arrhythmia within three months of inclusion; 8. Have other malignant tumor history; 9. Known allergy to Nimotuzumab, temozolomide or its analogues or any component of the prescription; 10. Unable to tolerate radiotherapy; 11. Other reasons that are not suitable to participate in this study according to the researcher's judgment.